Regulatory FDA approves Lilly obesity pill, triggering battle with Novo Nordisk pharminent April 1, 2026
Regulatory Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry pharminent April 1, 2026
M&A / Deals Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B pharminent April 1, 2026
Clinical Data Wave crashes on obesity drug update; Kodiak’s reboot pays dividends pharminent March 26, 2026
